BridgeBio Pharma (BBIO) Return on Sales (2019 - 2026)

BridgeBio Pharma has disclosed Return on Sales across 8 years of filings, most recently posting 0.01% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.01%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 4.0% YoY), and the FY2025 annual result was 0.01%, up 1.0% from the prior year.
• Return on Sales came in at 0.01% for Q1 2026 at BridgeBio Pharma, up from 0.01% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q1 2024 to a low of 4.34% in Q3 2022.
• The 5-year median for Return on Sales is 0.43% (2023), against an average of 0.65%.
• Across the five-year window, Return on Sales plunged 365 bps in 2022 and soared 391 bps in 2023, its largest moves.
• BridgeBio Pharma's Return on Sales stood at 0.78% in 2022, then tumbled by 42 bps to 1.1% in 2023, then soared by 59 bps to 0.45% in 2024, then jumped by 97 bps to 0.01% in 2025, then surged by 54 bps to 0.01% in 2026.
• The last three Return on Sales figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.